Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: comparison of patients over and under 75 years old
Front Med 2025:12;1538170 Doi: 10.3389/fmed.2025.1538170
This large French nationwide study by Fautrel et al. provided reassuring results for patients, who initiated tocilizumab (TCZ), aged at least 75 years compared to younger patients. Authors compared patient characteristics, tolerance of RA treatments, and long-term management with TCZ in patients with RA over and under 75 years of age.
Fautrel et al. identified no new safety signals in elderly patients. However, a personalized therapeutic approach must be adopted in routine medical practice to consider the risk profiles of elderly RA patients, notably risk factors for infections and cardiovascular events.
Keywords:
